1	1	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Introduction	_	_	NN	_	_	_	_	_


1	Influenza	_	_	NNP	_	_	_	_	_
2	A	_	_	NNP	_	_	_	_	_
3	virus	_	_	NN	_	_	_	_	_
4	(	_	_	-LRB-	_	_	_	_	_
5	IAV	_	_	NNP	_	_	_	_	_
6	)	_	_	-RRB-	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	a	_	_	DT	_	_	_	_	_
9	member	_	_	NN	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	Orthomyxoviridae	_	_	NNP	_	_	_	_	_
13	family	_	_	NN	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	is	_	_	VBZ	_	_	_	_	_
16	a	_	_	DT	_	_	_	_	_
17	negative-sense	_	_	JJ	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	single-stranded	_	_	JJ	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	enveloped	_	_	VBN	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	segmented	_	_	VBN	_	_	_	_	_
24	RNA	_	_	NN	_	_	_	_	_
25	virus	_	_	NN	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	IAV	_	_	NNP	_	_	_	_	_
2	usually	_	_	RB	_	_	_	_	_
3	infects	_	_	VBZ	_	_	_	_	_
4	epithelial	_	_	JJ	_	_	_	_	_
5	cells	_	_	NNS	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	upper	_	_	JJ	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	lower	_	_	JJR	_	_	_	_	_
11	respiratory	_	_	JJ	_	_	_	_	_
12	tracts	_	_	NNS	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	including	_	_	VBG	_	_	_	_	_
15	the	_	_	DT	_	_	_	_	_
16	nasal	_	_	JJ	_	_	_	_	_
17	mucosa	_	_	NN	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	trachea	_	_	NN	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	and	_	_	CC	_	_	_	_	_
22	lungs	_	_	NNS	_	_	_	_	_
23	,	_	_	,	_	_	_	_	_
24	with	_	_	IN	_	_	_	_	_
25	no	_	_	DT	_	_	_	_	_
26	evident	_	_	JJ	_	_	_	_	_
27	symptoms	_	_	NNS	_	_	_	_	_
28	during	_	_	IN	_	_	_	_	_
29	the	_	_	DT	_	_	_	_	_
30	early	_	_	JJ	_	_	_	_	_
31	phase	_	_	NN	_	_	_	_	_
32	of	_	_	IN	_	_	_	_	_
33	infection	_	_	NN	_	_	_	_	_
34	.	_	_	.	_	_	_	_	_


1	Once	_	_	IN	_	_	_	_	_
2	an	_	_	DT	_	_	_	_	_
3	influenza	_	_	NN	_	_	_	_	_
4	virus	_	_	NN	_	_	_	_	_
5	invasion	_	_	NN	_	_	_	_	_
6	occurs	_	_	VBZ	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	innate	_	_	JJ	_	_	_	_	_
9	immunity	_	_	NN	_	_	_	_	_
10	is	_	_	VBZ	_	_	_	_	_
11	activated	_	_	VBN	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	and	_	_	CC	_	_	_	_	_
14	interferons	_	_	NNS	_	_	_	_	_
15	are	_	_	VBP	_	_	_	_	_
16	secreted	_	_	VBN	_	_	_	_	_
17	by	_	_	IN	_	_	_	_	_
18	host	_	_	NN	_	_	_	_	_
19	cells	_	_	NNS	_	_	_	_	_
20	to	_	_	TO	_	_	_	_	_
21	limit	_	_	VB	_	_	_	_	_
22	the	_	_	DT	_	_	_	_	_
23	early	_	_	JJ	_	_	_	_	_
24	viral	_	_	JJ	_	_	_	_	_
25	proliferation	_	_	NN	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	Then	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	adaptive	_	_	JJ	_	_	_	_	_
4	immunity	_	_	NN	_	_	_	_	_
5	is	_	_	VBZ	_	_	_	_	_
6	activated	_	_	VBN	_	_	_	_	_
7	by	_	_	IN	_	_	_	_	_
8	other	_	_	JJ	_	_	_	_	_
9	cytokines	_	_	NNS	_	_	_	_	_
10	produced	_	_	VBN	_	_	_	_	_
11	during	_	_	IN	_	_	_	_	_
12	viral	_	_	JJ	_	_	_	_	_
13	infection	_	_	NN	_	_	_	_	_
14	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	in	_	_	IN	_	_	_	_	_
4	some	_	_	DT	_	_	_	_	_
5	cases	_	_	NNS	_	_	_	_	_
6	,	_	_	,	_	_	_	_	_
7	highly	_	_	RB	_	_	_	_	_
8	pathogenic	_	_	JJ	_	_	_	_	_
9	influenza	_	_	NN	_	_	_	_	_
10	viruses	_	_	NNS	_	_	_	_	_
11	induce	_	_	VBP	_	_	_	_	_
12	cytokine	_	_	NN	_	_	_	_	_
13	storms	_	_	NNS	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	a	_	_	DT	_	_	_	_	_
16	consequence	_	_	NN	_	_	_	_	_
17	of	_	_	IN	_	_	_	_	_
18	excessive	_	_	JJ	_	_	_	_	_
19	production	_	_	NN	_	_	_	_	_
20	of	_	_	IN	_	_	_	_	_
21	cytokines	_	_	NNS	_	_	_	_	_
22	and	_	_	CC	_	_	_	_	_
23	interferon	_	_	NN	_	_	_	_	_
24	,	_	_	,	_	_	_	_	_
25	resulting	_	_	VBG	_	_	_	_	_
26	in	_	_	IN	_	_	_	_	_
27	infections	_	_	NNS	_	_	_	_	_
28	and	_	_	CC	_	_	_	_	_
29	even	_	_	RB	_	_	_	_	_
30	death	_	_	NN	_	_	_	_	_
31	.	_	_	.	_	_	_	_	_


1	To	_	_	TO	_	_	_	_	_
2	facilitate	_	_	VB	_	_	_	_	_
3	virus	_	_	NN	_	_	_	_	_
4	replication	_	_	NN	_	_	_	_	_
5	in	_	_	IN	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	host	_	_	NN	_	_	_	_	_
8	cells	_	_	NNS	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	IAV	_	_	NNP	_	_	_	_	_
11	has	_	_	VBZ	_	_	_	_	_
12	evolved	_	_	VBN	_	_	_	_	_
13	strategies	_	_	NNS	_	_	_	_	_
14	to	_	_	TO	_	_	_	_	_
15	block	_	_	VB	_	_	_	_	_
16	the	_	_	DT	_	_	_	_	_
17	innate	_	_	JJ	_	_	_	_	_
18	and	_	_	CC	_	_	_	_	_
19	adaptive	_	_	JJ	_	_	_	_	_
20	immune	_	_	JJ	_	_	_	_	_
21	responses	_	_	NNS	_	_	_	_	_
22	of	_	_	IN	_	_	_	_	_
23	the	_	_	DT	_	_	_	_	_
24	host	_	_	NN	_	_	_	_	_
25	cells	_	_	NNS	_	_	_	_	_
26	and	_	_	CC	_	_	_	_	_
27	seize	_	_	VB	_	_	_	_	_
28	organelles	_	_	NNS	_	_	_	_	_
29	from	_	_	IN	_	_	_	_	_
30	host	_	_	NN	_	_	_	_	_
31	cells	_	_	NNS	_	_	_	_	_
32	to	_	_	TO	_	_	_	_	_
33	synthesize	_	_	VB	_	_	_	_	_
34	a	_	_	DT	_	_	_	_	_
35	large	_	_	JJ	_	_	_	_	_
36	number	_	_	NN	_	_	_	_	_
37	of	_	_	IN	_	_	_	_	_
38	metabolites	_	_	NNS	_	_	_	_	_
39	required	_	_	VBN	_	_	_	_	_
40	for	_	_	IN	_	_	_	_	_
41	viral	_	_	JJ	_	_	_	_	_
42	reproduction	_	_	NN	_	_	_	_	_
43	,	_	_	,	_	_	_	_	_
44	as	_	_	RB	_	_	_	_	_
45	well	_	_	RB	_	_	_	_	_
46	as	_	_	IN	_	_	_	_	_
47	energy	_	_	NN	_	_	_	_	_
48	for	_	_	IN	_	_	_	_	_
49	the	_	_	DT	_	_	_	_	_
50	packaging	_	_	NN	_	_	_	_	_
51	of	_	_	IN	_	_	_	_	_
52	the	_	_	DT	_	_	_	_	_
53	virus	_	_	NN	_	_	_	_	_
54	.	_	_	.	_	_	_	_	_


1	Enveloped	_	_	VBN	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	non-enveloped	_	_	JJ	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	DNA	_	_	NN	_	_	_	_	_
6	and	_	_	CC	_	_	_	_	_
7	RNA	_	_	NN	_	_	_	_	_
8	viruses	_	_	NNS	_	_	_	_	_
9	share	_	_	VBP	_	_	_	_	_
10	lipid	_	_	JJ	_	_	_	_	_
11	metabolites	_	_	NNS	_	_	_	_	_
12	in	_	_	IN	_	_	_	_	_
13	their	_	_	PRP$	_	_	_	_	_
14	replication	_	_	NN	_	_	_	_	_
15	cycles	_	_	NNS	_	_	_	_	_
16	to	_	_	TO	_	_	_	_	_
17	induce	_	_	VB	_	_	_	_	_
18	the	_	_	DT	_	_	_	_	_
19	formation	_	_	NN	_	_	_	_	_
20	of	_	_	IN	_	_	_	_	_
21	new	_	_	JJ	_	_	_	_	_
22	cytoplasmic	_	_	JJ	_	_	_	_	_
23	membrane	_	_	NN	_	_	_	_	_
24	structures	_	_	NNS	_	_	_	_	_
25	,	_	_	,	_	_	_	_	_
26	which	_	_	WDT	_	_	_	_	_
27	contribute	_	_	VBP	_	_	_	_	_
28	to	_	_	TO	_	_	_	_	_
29	the	_	_	DT	_	_	_	_	_
30	replication	_	_	NN	_	_	_	_	_
31	and	_	_	CC	_	_	_	_	_
32	packaging	_	_	NN	_	_	_	_	_
33	of	_	_	IN	_	_	_	_	_
34	the	_	_	DT	_	_	_	_	_
35	viral	_	_	JJ	_	_	_	_	_
36	genome	_	_	NN	_	_	_	_	_
37	.	_	_	.	_	_	_	_	_


1	Lipid	_	_	NN	_	_	_	_	_
2	metabolism	_	_	NN	_	_	_	_	_
3	also	_	_	RB	_	_	_	_	_
4	can	_	_	MD	_	_	_	_	_
5	block	_	_	VB	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	innate	_	_	JJ	_	_	_	_	_
8	immune	_	_	JJ	_	_	_	_	_
9	response	_	_	NN	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	host	_	_	NN	_	_	_	_	_
12	cells	_	_	NNS	_	_	_	_	_
13	to	_	_	TO	_	_	_	_	_
14	ensure	_	_	VB	_	_	_	_	_
15	the	_	_	DT	_	_	_	_	_
16	large-scale	_	_	JJ	_	_	_	_	_
17	replication	_	_	NN	_	_	_	_	_
18	of	_	_	IN	_	_	_	_	_
19	the	_	_	DT	_	_	_	_	_
20	virus	_	_	NN	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	Therefore	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	IAV	_	_	NNP	_	_	_	_	_
4	infection	_	_	NN	_	_	_	_	_
5	is	_	_	VBZ	_	_	_	_	_
6	linked	_	_	VBN	_	_	_	_	_
7	closely	_	_	RB	_	_	_	_	_
8	to	_	_	TO	_	_	_	_	_
9	metabolism	_	_	NN	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	and	_	_	CC	_	_	_	_	_
12	the	_	_	DT	_	_	_	_	_
13	proliferation	_	_	NN	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	the	_	_	DT	_	_	_	_	_
16	virus	_	_	NN	_	_	_	_	_
17	also	_	_	RB	_	_	_	_	_
18	is	_	_	VBZ	_	_	_	_	_
19	inseparable	_	_	JJ	_	_	_	_	_
20	from	_	_	IN	_	_	_	_	_
21	the	_	_	DT	_	_	_	_	_
22	host	_	_	NN	_	_	_	_	_
23	metabolism	_	_	NN	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	changing	_	_	VBG	_	_	_	_	_
3	trend	_	_	NN	_	_	_	_	_
4	in	_	_	IN	_	_	_	_	_
5	small	_	_	JJ	_	_	_	_	_
6	molecule	_	_	NN	_	_	_	_	_
7	metabolites	_	_	NNS	_	_	_	_	_
8	may	_	_	MD	_	_	_	_	_
9	serve	_	_	VB	_	_	_	_	_
10	as	_	_	IN	_	_	_	_	_
11	a	_	_	DT	_	_	_	_	_
12	characterization	_	_	NN	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	host	_	_	NN	_	_	_	_	_
15	–	_	_	:	_	_	_	_	_
16	pathogen	_	_	NN	_	_	_	_	_
17	interactions	_	_	NNS	_	_	_	_	_
18	to	_	_	TO	_	_	_	_	_
19	monitor	_	_	VB	_	_	_	_	_
20	immune	_	_	JJ	_	_	_	_	_
21	status	_	_	NN	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	Although	_	_	IN	_	_	_	_	_
2	significant	_	_	JJ	_	_	_	_	_
3	progress	_	_	NN	_	_	_	_	_
4	has	_	_	VBZ	_	_	_	_	_
5	been	_	_	VBN	_	_	_	_	_
6	made	_	_	VBN	_	_	_	_	_
7	toward	_	_	IN	_	_	_	_	_
8	an	_	_	DT	_	_	_	_	_
9	anti-influenza	_	_	JJ	_	_	_	_	_
10	virus	_	_	NN	_	_	_	_	_
11	drug	_	_	NN	_	_	_	_	_
12	discovery	_	_	NN	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	including	_	_	VBG	_	_	_	_	_
15	M2	_	_	NN	_	_	_	_	_
16	ion	_	_	NN	_	_	_	_	_
17	channel	_	_	NN	_	_	_	_	_
18	blockers	_	_	NNS	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	neuraminidase	_	_	NN	_	_	_	_	_
21	inhibitors	_	_	NNS	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	and	_	_	CC	_	_	_	_	_
24	polymerase	_	_	NN	_	_	_	_	_
25	inhibitors	_	_	NNS	_	_	_	_	_
26	,	_	_	,	_	_	_	_	_
27	challenges	_	_	NNS	_	_	_	_	_
28	posed	_	_	VBN	_	_	_	_	_
29	by	_	_	IN	_	_	_	_	_
30	drug	_	_	NN	_	_	_	_	_
31	toxicity	_	_	NN	_	_	_	_	_
32	and	_	_	CC	_	_	_	_	_
33	viruses	_	_	NNS	_	_	_	_	_
34	with	_	_	IN	_	_	_	_	_
35	genetic	_	_	JJ	_	_	_	_	_
36	resistance	_	_	NN	_	_	_	_	_
37	remain	_	_	VBP	_	_	_	_	_
38	a	_	_	DT	_	_	_	_	_
39	serious	_	_	JJ	_	_	_	_	_
40	problem	_	_	NN	_	_	_	_	_
41	.	_	_	.	_	_	_	_	_


1	Previous	_	_	JJ	_	_	_	_	_
2	research	_	_	NN	_	_	_	_	_
3	demonstrated	_	_	VBD	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	metabolic	_	_	JJ	_	_	_	_	_
6	effects	_	_	NNS	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	influenza	_	_	NN	_	_	_	_	_
9	virus	_	_	NN	_	_	_	_	_
10	infection	_	_	NN	_	_	_	_	_
11	in	_	_	IN	_	_	_	_	_
12	Madin	_	_	NNP	_	_	_	_	_
13	–	_	_	:	_	_	_	_	_
14	Darby	_	_	NNP	_	_	_	_	_
15	canine	_	_	NN	_	_	_	_	_
16	kidney	_	_	NN	_	_	_	_	_
17	(	_	_	-LRB-	_	_	_	_	_
18	MDCK	_	_	NNP	_	_	_	_	_
19	)	_	_	-RRB-	_	_	_	_	_
20	cells	_	_	NNS	_	_	_	_	_
21	,	_	_	,	_	_	_	_	_
22	displaying	_	_	VBG	_	_	_	_	_
23	the	_	_	DT	_	_	_	_	_
24	intra-	_	_	JJ	_	_	_	_	_
25	and	_	_	CC	_	_	_	_	_
26	extra-cellular	_	_	JJ	_	_	_	_	_
27	metabolite	_	_	NN	_	_	_	_	_
28	profiling	_	_	NN	_	_	_	_	_
29	upon	_	_	IN	_	_	_	_	_
30	IAV	_	_	NNP	_	_	_	_	_
31	infection	_	_	NN	_	_	_	_	_
32	.	_	_	.	_	_	_	_	_


1	Little	_	_	RB	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	known	_	_	VBN	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	however	_	_	RB	_	_	_	_	_
6	,	_	_	,	_	_	_	_	_
7	about	_	_	IN	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	systemic	_	_	JJ	_	_	_	_	_
10	metabolic	_	_	JJ	_	_	_	_	_
11	dynamics	_	_	NNS	_	_	_	_	_
12	during	_	_	IN	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	early	_	_	JJ	_	_	_	_	_
15	stage	_	_	NN	_	_	_	_	_
16	of	_	_	IN	_	_	_	_	_
17	virus	_	_	NN	_	_	_	_	_
18	infection	_	_	NN	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	During	_	_	IN	_	_	_	_	_
2	our	_	_	PRP$	_	_	_	_	_
3	study	_	_	NN	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	we	_	_	PRP	_	_	_	_	_
6	analyze	_	_	VBP	_	_	_	_	_
7	changes	_	_	NNS	_	_	_	_	_
8	in	_	_	IN	_	_	_	_	_
9	metabolism	_	_	NN	_	_	_	_	_
10	upon	_	_	IN	_	_	_	_	_
11	influenza	_	_	NN	_	_	_	_	_
12	virus	_	_	NN	_	_	_	_	_
13	infection	_	_	NN	_	_	_	_	_
14	in	_	_	IN	_	_	_	_	_
15	human	_	_	JJ	_	_	_	_	_
16	cells	_	_	NNS	_	_	_	_	_
17	during	_	_	IN	_	_	_	_	_
18	the	_	_	DT	_	_	_	_	_
19	first	_	_	JJ	_	_	_	_	_
20	infectious	_	_	JJ	_	_	_	_	_
21	cycle	_	_	NN	_	_	_	_	_
22	via	_	_	IN	_	_	_	_	_
23	metabolomics	_	_	NNS	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	Early	_	_	JJ	_	_	_	_	_
2	metabolite	_	_	NN	_	_	_	_	_
3	analysis	_	_	NN	_	_	_	_	_
4	will	_	_	MD	_	_	_	_	_
5	throw	_	_	VB	_	_	_	_	_
6	new	_	_	JJ	_	_	_	_	_
7	light	_	_	NN	_	_	_	_	_
8	on	_	_	IN	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	activation	_	_	NN	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	the	_	_	DT	_	_	_	_	_
13	innate	_	_	JJ	_	_	_	_	_
14	immune	_	_	JJ	_	_	_	_	_
15	metabolism	_	_	NN	_	_	_	_	_
16	.	_	_	.	_	_	_	_	_


1	We	_	_	PRP	_	_	_	_	_
2	believe	_	_	VBP	_	_	_	_	_
3	that	_	_	IN	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	results	_	_	NNS	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	this	_	_	DT	_	_	_	_	_
8	work	_	_	NN	_	_	_	_	_
9	will	_	_	MD	_	_	_	_	_
10	elucidate	_	_	VB	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	activation	_	_	NN	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	innate	_	_	JJ	_	_	_	_	_
15	immunity	_	_	NN	_	_	_	_	_
16	to	_	_	TO	_	_	_	_	_
17	viral	_	_	JJ	_	_	_	_	_
18	infection	_	_	NN	_	_	_	_	_
19	from	_	_	IN	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	perspective	_	_	NN	_	_	_	_	_
22	of	_	_	IN	_	_	_	_	_
23	the	_	_	DT	_	_	_	_	_
24	host	_	_	NN	_	_	_	_	_
25	and	_	_	CC	_	_	_	_	_
26	provide	_	_	VB	_	_	_	_	_
27	new	_	_	JJ	_	_	_	_	_
28	control	_	_	NN	_	_	_	_	_
29	strategies	_	_	NNS	_	_	_	_	_
30	for	_	_	IN	_	_	_	_	_
31	the	_	_	DT	_	_	_	_	_
32	development	_	_	NN	_	_	_	_	_
33	of	_	_	IN	_	_	_	_	_
34	novel	_	_	JJ	_	_	_	_	_
35	drugs	_	_	NNS	_	_	_	_	_
36	and	_	_	CC	_	_	_	_	_
37	the	_	_	DT	_	_	_	_	_
38	treatment	_	_	NN	_	_	_	_	_
39	and	_	_	CC	_	_	_	_	_
40	prevention	_	_	NN	_	_	_	_	_
41	of	_	_	IN	_	_	_	_	_
42	influenza	_	_	NN	_	_	_	_	_
43	virus	_	_	NN	_	_	_	_	_
44	infection	_	_	NN	_	_	_	_	_
45	.	_	_	.	_	_	_	_	_

